Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259308 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
279
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Conditions

Interventions

Sponsor

Shire